Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of substances that induce irf8 expression in the preparation of drugs for treating liver cancer

A technology for the treatment of liver cancer, substances, applied in the field of medicine

Active Publication Date: 2021-07-27
CHINA PHARM UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The purpose of the present invention is to address the current problem of androgen receptor drug resistance, and to provide the application of substances that induce IRF8 expression in the preparation of drugs for the auxiliary treatment of diseases caused by abnormal expression of androgen receptor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of substances that induce irf8 expression in the preparation of drugs for treating liver cancer
  • Application of substances that induce irf8 expression in the preparation of drugs for treating liver cancer
  • Application of substances that induce irf8 expression in the preparation of drugs for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1 Immunohistochemistry

[0065] Fresh prostate cancer and benign prostatic hyperplasia tissues were collected from Jiangsu Provincial Hospital of Traditional Chinese Medicine. After quick freezing in liquid nitrogen, paraffin sections were prepared. Prostate cancer tissue chips (HPro-Ade180PG-02, 180 points) were purchased from Shanghai Xinchao Company and commissioned for immunohistochemistry Detect the expression of IRF8, and invite senior pathologists to interpret the immunohistochemical results:

[0066] (1) Judgment of staining positive rate: First, observe the tissue point in the entire field of view under a low-magnification microscope, and then select 3 fields of view with different staining intensities for interpretation under a high-power microscope. Randomly record 100 cells in one field of view, and then record the percentage of positive cells in the 100 cells X1%. After looking at the percentages of positive cells in the other two fields of view, X2...

Embodiment 2

[0077] 2.1 DHT can up-regulate the expression of IRF8

[0078]As the ligand of AR, androgen plays a crucial role in the growth and malignant transformation of prostate cancer cells mediated by AR. Abnormal activation of the Androgen-AR signaling pathway is common in the development of prostate cancer. We found that with the increase of the pathological grade of prostate cancer, the expression of IRF8 increased, and the expression of IRF8 was positively correlated with the expression of AR. These studies suggest that there is a link between IRF8 and AR. Studies have shown that a group of ISG proteins in prostate cells can also be regulated by androgen as androgen-stimulated genes. In this example, we detected whether the expression of IRF8 was regulated by the AR signaling pathway. The AR-positive prostate cancer cell line LNCaP was pretreated with 5% carbon-adsorbed serum C-FBS for 24 hrs, and then stimulated with 10 nM DHT for 24 hrs to detect the expression of IRF8 by imm...

Embodiment 3

[0081] Example 3 LNCaP cells knock down IRF8 expression cell proliferation to accelerate

[0082] 3.1 Design and construction of IRF8 knockout cell lines LNCaP-shNC, LNCaP-shRNA1, LNCaP-shRNA2.

[0083] 3.1.1 Design of Oligo

[0084] DNA oligo was designed using Designer3.0 (Genepharma) software, and the primers were synthesized by Shanghai Gemma Pharmaceutical Technology Co., Ltd. The loop structure in the LV3-shRNA template uses TTCAAGAGA to avoid the formation of termination signals. The 5' end of the sense strand contains GATCC, which is complementary to the sticky end formed after BamHI digestion; the 5' end of the antisense strand contains AATTC, which is complementary to the sticky end formed after EcoRI digestion.

[0085] Sense strand: 5'-GATCC-(GN18)-(TTCAAGAGA)-(N18C)-TTTTTTG-3'

[0086] Antisense strand: 3'-G(CN18)-(AAGTTCTCT)-(N18G)-AAAAAACTTAA-5'

[0087] Table 3 Designed DNA Oligo

[0088]

[0089]

[0090] 3.1.2 Annealing of LV3-shDNA template

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of a substance that induces IRF8 expression in the preparation of medicines for treating diseases caused by abnormal expression of androgen receptors. The present invention finds that IRF8 can directly regulate the proliferation of prostate cancer and liver cancer cells, and the expression of IRF8 can regulate the sensitivity of prostate cancer cells to the AR antagonist Enz, and knockdown of IRF8 can lead to apoptosis resistance of prostate cancer cells to Enz. Substances that induce IRF8 expression, such as IFNα, up-regulate the expression of IRF8 through AR, and then participate in the regulation of the sensitivity of prostate cancer cells to Enz. In clinical trials, IFNα combined with maximal androgen deprivation endocrine therapy can enhance the curative effect of prostate cancer patients. It can be seen that substances that induce IRF8 expression can be combined with androgen receptor antagonists to enhance the sensitivity of clinical patients with low IRF8 expression to androgen receptor antagonists, improve the efficacy of androgen receptor antagonists, and delay the occurrence of drug resistance.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the application of substances that induce IRF8 expression in the preparation of medicines for treating diseases caused by abnormal expression of androgen receptors. Background technique [0002] In European and American countries, prostate cancer is the second most common male malignant tumor in terms of incidence and mortality. Although the incidence of prostate cancer in my country is lower than that in western countries, it is increasing significantly with the change of lifestyle and the aging of the population. trend. It is estimated that by 2020, the incidence of prostate cancer will be as high as 40 / 100,000, and the annual new cases will reach 350,000, which is equivalent to the incidence of liver cancer. [0003] The initial prostate cancer is hormone-dependent. At that time, endocrine therapy is sensitive, the symptoms of prostate cancer improve, and the disease process is delayed. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K45/06A61K38/21A61P1/16A61P13/08A61P35/00
CPCA61K38/212A61K45/00A61K45/06A61K2300/00
Inventor 杨勇吴红茜赵志立李岩高晓芳赵伟毛杰
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com